Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
Open-label, single-arm, prospective multicenter phase II clinical trial to determine the
efficacy and safety combined pembrolizumab and lenvatinib as maintenance therapy after
definitive radiochemotherapy of locally advanced head and neck squamous cell carcinoma
(HNSCC).